Explore how proteomics in biomarker discovery accelerates diagnostic assay development and improves clinical validation.

This article explores multiplexing applications in biopharma and highlights key assay development factors to consider.

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...

ROCKVILLE, Md.--(BUSINESS WIRE)--BrainScope, a leader in brain diagnostics, today announced the successful completion of the proof-of-concept phase for a novel brain activity-based biomarker for the ...

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the ...

Hello, and welcome to Herantis Pharma's Phase Ib Biomarker Data webinar. I am CEO, Antti Vuolanto, joined today by CSO, Henri Huttunen; and CFO, Tone Kvale. We are really excited to discuss yesterday ...